3,4-Dihydroxy-L-phenylalanine (L-DOPA)

<strong>3,4-Dihydroxy-L-phenylalanine (L-DOPA)</strong>_x000D_ <strong>Catalog number:</strong> B2014887_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 g_x000D_ <strong>Molecular Weight or Concentration:</strong> 197.19 g/mol_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> RT_x000D_ <strong>Keywords:</strong> 3-(3,4-Dihydroxyphenyl)-L-alanine, L-3-Hydroxytyrosine, L-DOPA, Levodopa_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease Mov Disord. 2010 Nov 15;25(15):2649-53._x000D_ 2: Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease Mov Disord. 2008;23 Suppl 3:S497-508._x000D_ 3: Haddad F, Sawalha M, Khawaja Y, Najjar A, Karaman R. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease Molecules. 2017 Dec 25;23(1):40._x000D_ 4: Levodopa Nurs Times. 2005 Nov 22-28;101(47):27._x000D_ 5: Ayyadurai N, Prabhu NS, Deepankumar K, Jang YJ, Chitrapriya N, Song E, Lee N, Kim SK, Kim BG, Soundrarajan N, Lee S, Cha HJ, Budisa N, Yun H. Bioconjugation of L-3,4-dihydroxyphenylalanine containing protein with a polysaccharide Bioconjug Chem. 2011 Apr 20;22(4):551-5._x000D_ 6: Ihara M, Tsuchiya Y, Sawasaki Y, Hisaka A, Takehana H, Tomimoto K, Yano M. A new potential prodrug to improve the duration of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine J Pharm Sci. 1989 Jul;78(7):525-9._x000D_ 7: Levodopa for parkinsonism Br Med J. 1971 Jan 30;1(5743):244-5._x000D_ 8: Shpiner DS, Bette S, Di Luca DG, Margolesky J. CVT-301 for the treatment of Parkinson's disease Expert Rev Neurother. 2019 Jul;19(7):603-611._x000D_ 9: Abbruzzese G. Optimising levodopa therapy Neurol Sci. 2008 Dec;29 Suppl 5:S377-9._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/8412892">10: Creasey HM, Broe GA. Parkinson's disease Med J Aust. 1993 Aug 16;159(4):249-53. </a>_x000D_ _x000D_ <strong>Products Related to 3,4-Dihydroxy-L-phenylalanine (L-DOPA) can be found at</strong> <a href="https://moleculardepot.com/product-category/Chemicals/"> Chemicals</a>